Proven efficacy in reducing the risk of ischemic stroke1

Explore the primary endpoint, secondary endpoints, and a subgroup analysis.

Study design

The OCEANIC-STROKE study was a multicenter, randomized, placebo-controlled, double-blind, and event-driven phase 3 study designed to demonstrate the efficacy and safety of SUNHARBO (50 mg once daily) in combination with antiplatelet therapy (APT) for the prevention of ischemic stroke in adults 18 years or older after an index event of acute non-cardioembolic ischemic stroke (NIH Stroke Scale ≤15) or high-risk transient ischemic attack (TIA) (ABCD2 score ≥6). Patients were randomized within 72 hours after onset of symptoms.1

Full study design

ABCD2=Age, Blood Pressure, Clinical Features, Duration, and Diabetes.

 

    SUNHARBO + APT significantly reduced ischemic stroke vs APT alone1

    Time to first occurrence of ischemic stroke vs APT alone1

    efficacy-graph

    Consistent treatment effect for the primary endpoint was observed across all predefined subgroups, including sex, age, type of index event, stroke severity, dual APT, thrombolysis, and/or endovascular therapy.

    *Cumulative incidence curves are estimated by Aalen–Johansen method, truncated at Day 820.2

    †Statistically significant.

    ‡Year 1: NNT = 1 ÷ ARR = 1 ÷ 0.0185 = 54.

    §Year 2: NNT = 1 ÷ ARR = 1 ÷ 0.0217 = 46.

    ARR=absolute risk reduction; CI=confidence interval; HR=hazard ratio; NCIS=non-cardioembolic ischemic stroke; NNT=number needed to treat; TIA=transient ischemic attack. 

    SUNHARBO + APT reduced the risk of secondary endpoints vs APT alone1

    The results of these secondary endpoints were primarily driven by reduction of ischemic stroke, and there was no difference for all cause-mortality.

    Time to first occurrence

    graph-1
    • Statistically significant.

    CI=confidence interval; CV=cardiovascular; HR=hazard ratio; MI=myocardial infarction; mRS=Modified Rankin Scale; TIA=transient ischemic attack.

    Consistent treatment effect on primary endpoint across prespecified subgroups vs APT alone2

    Risk of ischemic stroke by baseline characteristics (intent-to-treat population)1

    by-population-graph

    CUIN=cumulative incidence; EVT=endovascular therapy; IVT=Intravenous thrombolysis; P2Y12=purinergic receptor Y12; TIA=transient ischemic attack.

    References

    • SUNHARBO (asundexian) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; November 2026.
    • Sharma M, Dong Q, Hirano T, et al; OCEANIC-STROKE Investigators. Asundexian for secondary stroke prevention. N Engl J Med. 2026;394(15):1467-1479. doi:10.1056/NEJMoa2513880